AGN Neuro

Algernon NeuroScience, a private equity subsidiary of Algernon Pharmaceuticals, aims to advance the company's DMT stroke research program. AGN Neuro has submitted a Form 1-A offering statement to the U.S. Securities and Exchange Commission, seeking qualification to raise up to $10 million for AGN Neuro under Tier 2 Regulation A+ offering rules. The offering includes 37.5% of AGN Neuro’s common stock (including the maximum number of bonus shares), with majority ownership retained by AGN Pharma.